Aligos Therapeutics, Inc. (ALGS)

NASDAQ: ALGS · IEX Real-Time Price · USD
1.29
-0.02 (-1.53%)
Jun 29, 2022 12:06 PM EDT - Market open
-1.53%
Market Cap 55.08M
Revenue (ttm) n/a
Net Income (ttm) -136.27M
Shares Out 42.70M
EPS (ttm) -3.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 18,577
Open 1.34
Previous Close 1.31
Day's Range 1.23 - 1.34
52-Week Range 1.03 - 21.90
Beta n/a
Analysts Buy
Price Target 4.72 (+265.9%)
Earnings Date Aug 4, 2022

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secreti... [Read more...]

Industry Biotechnology
IPO Date Oct 16, 2020
Employees 95
Stock Exchange NASDAQ
Ticker Symbol ALGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is 4.72, which is an increase of 265.89% from the latest price.

Price Target
$4.72
(265.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unm...

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unm...

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (ALG-...

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Aligos Therapeutics, Inc. ("Aligos" or the "Company") (NASDAQ: ALGS). Such inves...

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)---- $ALGS #investigation--Aligos Therapeutics, Inc. (ALGS) Halted Development of its Lead Drug Candidate

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG...

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete

ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders...

NEW YORK--(BUSINESS WIRE)-- #Aligos--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Aligos Therapeutics, Inc. (“Aligos” or th...

Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unm...

Aligos (ALGS) Stock Down on Hepatitis Drug Development Halt

Aligos Therapeutics' (ALGS) phase I study evaluating its chronic hepatitis B candidate, ALG-010133, did not achieve sufficient activity against the disease.

Why Aligos Therapeutics Stock Crumbled Today

The company is pulling the plug on a once-promising treatment targeting hepatitis B.

Aligos Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-H...

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

Vipergen Establishes Research Partnership with Aligos Therapeutics Focused on DNA Encoded Library (DEL)-Based Drug Di...

COPENHAGEN, Denmark, Nov. 23, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of ...

Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio...

Several clinical and nonclinical posters to be presented at the conference

All You Need to Know About Aligos Therapeutics, Inc. (ALGS) Rating Upgrade to Buy

Aligos Therapeutics, Inc. (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Can Aligos Therapeutics, Inc. (ALGS) Climb 91% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Aligos Therapeutics, Inc. (ALGS) points to a 91.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results

Dosing of ALG-020572 (ASO) in healthy volunteers underway

Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD'S The ...

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address un...

Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in...

Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates in clinical trials Aligos now evaluating three of its four chronic hepatitis B (CHB) portfolio drug candidates...

Aligos Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...